The Epidemiological Surveillance of Mesothelioma Mortality in Italy as a Tool for the Prevention of Asbestos Exposure.

Int J Environ Res Public Health

Department of Environment and Health, Istituto Superiore di Sanità, 00161 Rome, Italy.

Published: May 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

As part of a surveillance plan active since the early 1990s, this study evaluates malignant mesothelioma (MM) mortality for the time-window 2010-2019 in Italy, a country that banned asbestos in 1992. National and regional mortality rates for MM, and municipal standardized mortality ratios (all mesotheliomas, pleural (MPM) and peritoneal (MPeM)), by gender and age group were calculated. A municipal clustering analysis was also performed. There were 15,446 deaths from MM (11,161 males, 3.8 × 100,000; 4285 females, 1.1 × 100,000), of which 12,496 were MPM and 661 were MPeM. In the study period, 266 people ≤50 years died from MM. A slightly decreasing rate among males since 2014 was observed. The areas at major risk hosted asbestos-cement plants, asbestos mines (chrysotile in Balangero), shipyards, petrochemical and chemical plants, and refineries. Female mortality excesses particularly were found in municipalities with a fluoro-edenite-contaminated mine (Biancavilla) and textile facilities. Excesses were also found in a region with the presence of natural asbestos fibres and in males living in two small islands. The Italian National Prevention Plan stated recommendations to eliminate asbestos exposures and to implement health surveillance and healthcare for people exposed to asbestos.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252364PMC
http://dx.doi.org/10.3390/ijerph20115957DOI Listing

Publication Analysis

Top Keywords

mesothelioma mortality
8
asbestos
6
mortality
5
epidemiological surveillance
4
surveillance mesothelioma
4
mortality italy
4
italy tool
4
tool prevention
4
prevention asbestos
4
asbestos exposure
4

Similar Publications

Background: Bladder cancer is characterized by its heterogeneous nature and high propensity for recurrence and progression. The absence of reliable diagnostic and prognostic biomarkers to accurately identify high-risk patients further complicates the clinical management of the disease. MOC-31, an antibody that targets epithelial cell adhesion molecule (EpCAM), is utilized to distinguish between mesothelioma and metastatic cancer, but its clinical utility, prognostic value and functional dynamics in bladder cancer have yet to be verified.

View Article and Find Full Text PDF

There is limited evidence regarding the second-line treatment for patients with unresectable, advanced, or metastatic pleural mesothelioma receiving first-line nivolumab plus ipilimumab combination immunotherapy. Although chemotherapy with pemetrexed and a platinum-based agent is empirically administered as the second-line treatment in clinical practice, its effect in patients after nivolumab plus ipilimumab remains unclear. Therefore, this retrospective observational study aimed to elucidate the efficacy of pemetrexed plus platinum therapy as a second-line treatment for pleural mesothelioma after first-line nivolumab-ipilimumab immunotherapy.

View Article and Find Full Text PDF

Insights into the molecular mechanisms underlying the function of lysyl oxidase like 1 in cancers.

PeerJ

August 2025

Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Dali University, Dali, Yunnan, China.

Cancer is one of the primary causes of human mortality and a significant barrier to increasing human life expectancy. The effective screening, early diagnosis, and treatment of cancer have long been clinical challenges, and thus new biomarkers or molecular targets must be identified to improve the diagnosis and treatment of cancer patients. Lysyl oxidase like 1 (LOXL1), a secreted copper-dependent amine oxidase, is commonly expressed in a variety of cell types.

View Article and Find Full Text PDF

Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma.

Lung Cancer

September 2025

Unit of Bioinformatics for Precision Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain; Molecular Biology CORE. Center for Biomedical Diagnostics (CDB), Hospital Clínic de Barcelona. Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical

Unlabelled: Pleural mesothelioma (PM) is a rare and lethal cancer with limited treatment options. Intratumor heterogeneity (ITH) has been postulated as one of the reasons for the poor treatment response observed in most PM patients. In this regard, we aimed to characterize ITH in a multi-site tumor specimen using single-cell RNA-sequencing (scRNA-seq).

View Article and Find Full Text PDF

Global trends, future projections, and epidemiological associations of Mesothelioma: A comprehensive analysis from 1980 to 2050.

Cancer Epidemiol

August 2025

School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai

Background: Malignant mesothelioma is a rare but aggressive cancer primarily caused by occupational asbestos exposure. This study aims to comprehensively assess global mesothelioma incidence and mortality trends, examine their associations with the Human Development Index (HDI), project future burden through 2050, and investigate epidemiological correlations with other malignancies.

Methods: We extracted mesothelioma incidence and mortality data from GBD 2021 and GLOBOCAN 2022, covering 204 and 185 countries from 1980 to 2022, respectively.

View Article and Find Full Text PDF